A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth

International Journal of Cancer

Volumn 129, Issue 8, 2011, Pages 2013-2024

  Roovers, Rob C ^a   Vosjan, Maria J W D ^b   Laeremans, Toon ^c   El Khoulati, Rachid ^a   De Bruin, Renée C G ^a   Ferguson, Kathryn M ^d   Verkleij, Arie J ^a   Van Dongen, Guus A M S ^b   Van Bergen En Henegouwen, Paul M P ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c ABLYNX NV   (Belgium)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

EGFR; nanobody; signalling; targeted therapy; tumour

Indexed keywords

27C7 NANOBODY; 27E5 NANOBODY; 27E8 NANOBODY; 27H7 NANOBODY; 38G7 NANOBODY; 7C12 NANOBODY; 7D12 7D12 ALB1 NANOBODY; 7D12 7D12 NANOBODY; 7D12 9G8 NANOBODY; 7D12 NANOBODY; 9G8 7D12 NANOBODY; 9G8 9G8 NANOBODY; 9G8 NANOBODY; ANTIBODY; CETUXIMAB; COOPERATIVE NANOBODY 1; EPIDERMAL GROWTH FACTOR RECEPTOR; MATUZUMAB; NANOBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING COMPETITION; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DISSOCIATION CONSTANT; GROWTH INHIBITION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RECEPTOR BLOCKING; TUMOR; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; EPITOPES; HUMANS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SINGLE-CHAIN ANTIBODIES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052030449     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26145     Document Type: Article

References (47)

1. Garrett TP, McKern NM, Lou M, Elleman TC, Adams TE, Lovrecz GO, Zhu HJ, Walker F, Frenkel MJ, Hoyne PA, Jorissen RN, Nice EC, et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha. Cell 2002; 110: 763-73. (Pubitemid 35283965)
2. Ogiso H, Ishitani R, Nureki O, Fukai S, Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M, Yokoyama S,. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110: 775-87. (Pubitemid 35291060)
3. Ferguson KM,. Structure-based view of epidermal growth factor receptor regulation. Annu Rev Biophys 2008; 37: 353-73.
4. Yarden Y,. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001; 37 (Suppl 4): S3-S8. (Pubitemid 32938123)
5. Jorissen RN, Walker F, Pouliot N, Garrett TP, Ward CW, Burgess AW,. Epidermal growth factor receptor: mechanisms of activation and signalling. Exp Cell Res 2003; 284: 31-53. (Pubitemid 36331965)
6. Buday L, Downward J,. Epidermal growth factor regulates p21ras through the formation of a complex of receptor, Grb2 adapter protein, and Sos nucleotide exchange factor. Cell 1993; 73: 611-20. (Pubitemid 23143358)
7. Gale NW, Kaplan S, Lowenstein EJ, Schlessinger J, Bar-Sagi D,. Grb2 mediates the EGF-dependent activation of guanine nucleotide exchange on Ras. Nature 1993; 363: 88-92. (Pubitemid 23144969)
8. Soltoff SP, Carraway KL, III, Prigent SA, Gullick WG, Cantley LC,. ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor. Mol Cell Biol 1994; 14: 3550-8. (Pubitemid 24160762)
9. Prigent SA, Gullick WJ,. Identification of c-erbB-3 binding sites for phosphatidylinositol 3′-kinase and SHC using an EGF receptor/c-erbB-3 chimera. EMBO J 1994; 13: 2831-41.
10. Uberall I, Kolar Z, Trojanec R, Berkovcova J, Hajduch M,. The status and role of ErbB receptors in human cancer. Exp Mol Pathol 2008; 84: 79-89.
11. Robertson SC, Tynan J, Donoghue DJ,. RTK mutations and human syndromes: when good receptors turn bad. Trends Genet 2000; 16: 368.
12. Patel DK,. Clinical use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 2008; 28: 31S-41S.
13. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM,. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11. (Pubitemid 40544648)
14. Li S, Kussie P, Ferguson KM,. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 2008; 16: 216-27. (Pubitemid 351215209)
15. Schmiedel J, Blaukat A, Li S, Knochel T, Ferguson KM,. Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell 2008; 13: 365-73. (Pubitemid 351446197)
16. Schmitz KR, Ferguson KM,. Interaction of antibodies with ErbB receptor extracellular regions. Exp Cell Res 2009; 315: 659-70.
17. Johns TG, Adams TE, Cochran JR, Hall NE, Hoyne PA, Olsen MJ, Kim YS, Rothacker J, Nice EC, Walker F, Ritter G, Jungbluth AA, et al. Identification of the epitope for the epidermal growth factor receptor-specific monoclonal antibody 806 reveals that it preferentially recognizes an untethered form of the receptor. J Biol Chem 2004; 279: 30375-84. (Pubitemid 38937965)
18. Garrett TP, Burgess AW, Gan HK, Luwor RB, Cartwright G, Walker F, Orchard SG, Clayton AH, Nice EC, Rothacker J, Catimel B, Cavenee WK, et al. Antibodies specifically targeting a locally misfolded region of tumor associated EGFR. Proc Natl Acad Sci USA 2009; 106: 5082-7.
19. Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, Cocklin S, Williams JC, Papazoglou E, Rodeck U,. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic MABS C225 and 425. Cancer Biol Ther 2008; 7: 726-33.
20. Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen en Henegouwen PM,. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies. Cancer Immunol Immunother 2007; 56: 303-17. (Pubitemid 46035901)
21. Els Conrath K, Lauwereys M, Wyns L, Muyldermans S,. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 2001; 276: 7346-50.
22. Roovers RC, van Dongen GA, van Bergen en Henegouwen PM,. Nanobodies in therapeutic applications. Curr Opin Mol Ther 2007; 9: 327-35. (Pubitemid 47255665)
23. Dennis MS, Zhang M, Meng YG, Kadkhodayan M, Kirchhofer D, Combs D, Damico LA,. Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J Biol Chem 2002; 277: 35035-43.
24. Tijink BM, Laeremans T, Budde M, Stigter-van Walsum M, Dreier T, de Haard HJ, Leemans CR, van Dongen GA,. Improved tumor targeting of anti-epidermal growth factor receptor nanobodies through albumin binding: taking advantage of modular nanobody technology. Mol Cancer Ther 2008; 7: 2288-97.
25. Roovers RC, Henderikx P, Helfrich W, van der Linden E, Reurs A, de Bruine AP, Arends JW, de Leij L, Hoogenboom HR,. High-affinity recombinant phage antibodies to the pan-carcinoma marker epithelial glycoprotein-2 for tumour targeting. Br J Cancer 1998; 78: 1407-16. (Pubitemid 28517535)
26. Giard DJ, Aaronson SA, Todaro GJ, Arnstein P, Kersey JH, Dosik H, Parks WP,. In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors. J Natl Cancer Inst 1973; 51: 1417-23.
27. Merlino GT, Xu YH, Ishii S, Clark AJ, Semba K, Toyoshima K, Yamamoto T, Pastan I,. Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science 1984; 224: 417-19. (Pubitemid 14134005)
28. Honegger AM, Dull TJ, Felder S, Van Obberghen E, Bellot F, Szapary D, Schmidt A, Ullrich A, Schlessinger J,. Point mutation at the ATP binding site of EGF receptor abolishes protein-tyrosine kinase activity and alters cellular routing. Cell 1987; 51: 199-209.
29. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M,. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 1987; 252: 549-60. (Pubitemid 17026484)
30. Haisma HJ, Grill J, Curiel DT, Hoogeland S, van Beusechem VW, Pinedo HM, Gerritsen WR,. Targeting of adenoviral vectors through a bispecific single-chain antibody. Cancer Gene Ther 2000; 7: 901-4. (Pubitemid 30437291)
31. De Haard HJ, Bezemer S, Ledeboer AM, Muller WH, Boender PJ, Moineau S, Coppelmans MC, Verkleij AJ, Frenken LG, Verrips CT,. Llama antibodies against a lactococcal protein located at the tip of the phage tail prevent phage infection. J Bacteriol 2005; 187: 4531-41. (Pubitemid 40880965)
32. Hofman EG, Ruonala MO, Bader AN, van den Heuvel D, Voortman J, Roovers RC, Verkleij AJ, Gerritsen HC, van Bergen en Henegouwen PM,. EGF induces coalescence of different lipid rafts. J Cell Sci 2008; 121: 2519-28.
33. Ferguson KM, Darling PJ, Mohan MJ, Macatee TL, Lemmon MA,. Extracellular domains drive homo- but not hetero-dimerization of erbB receptors. EMBO J 2000; 19: 4632-43.
34. Hawkins RE, Russell SJ, Winter G,. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J Mol Biol 1992; 226: 889-96.
35. Marks JD, Hoogenboom HR, Bonnert TP, McCafferty J, Griffiths AD, Winter G,. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J Mol Biol 1991; 222: 581-97.
36. Meulemans EV, Slobbe R, Wasterval P, Ramaekers FC, van Eys GJ,. Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibody. J Mol Biol 1994; 244: 353-60. (Pubitemid 24378162)
37. Stemmer WP, Crameri A, Ha KD, Brennan TM, Heyneker HL,. Single-step assembly of a gene and entire plasmid from large numbers of oligodeoxyribonucleotides. Gene 1995; 164: 49-53.
38. Sanger F, Nicklen S, Coulson AR,. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-7.
39. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR,. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12. (Pubitemid 20213250)
40. Frieden E, Lipsett MB, Winzler RJ,. Methods for labeling thyroxine with radioactive iodine. Science 1948; 107: 353-4.
41. Visser GW, Klok RP, Gebbinck JW, ter Linden T, van Dongen GA, Molthoff CF,. Optimal quality (131)I-monoclonal antibodies on high-dose labeling in a large reaction volume and temporarily coating the antibody with IODO-GEN. J Nucl Med 2001; 42: 509-19. (Pubitemid 32207405)
42. Coppieters K, Dreier T, Silence K, de Haard H, Lauwereys M, Casteels P, Beirnaert E, Jonckheere H, Van de Wiele C, Staelens L, Hostens J, Revets H, et al. Formatted anti-tumor necrosis factor alpha VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen-induced arthritis. Arthritis Rheum 2006; 54: 1856-66. (Pubitemid 43877935)
43. Neri D, Momo M, Prospero T, Winter G,. High-affinity antigen binding by chelating recombinant antibodies (CRAbs). J Mol Biol 1995; 246: 367-73.
44. Cortez-Retamozo V, Lauwereys M, Hassanzadeh Gh G, Gobert M, Conrath K, Muyldermans S, De Baetselier P, Revets H,. Efficient tumor targeting by single-domain antibody fragments of camels. Int J Cancer 2002; 98: 456-62. (Pubitemid 34188691)
45. Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P, Lahoutte T,. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 2008; 49: 788-95. (Pubitemid 351717545)
46. Clayton A, Walker F, Orchard S, Henderson C, Fuchs D, Rothacker J, Nice E, Burgess A,. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem 2005; 280: 30392-9. (Pubitemid 41216222)
47. Hofman EG, Bader AN, Voortman J, Van den Heuvel DJ, Sigismund S, Verkleij AJ, Gerritsen HC, Van Bergen en Henegouwen PM,. Ligand-induced epidermal growth factor receptor (EGFR) oligomerization is kinase-dependent and enhances internalization. J Biol Chem 2010; 285: 39481-9.